Education
About Us
Working with TipRanks
Follow Us
Metsera, Inc. (MTSR)
NASDAQ:MTSR
MTSR Stock Chart & Stats
Day’s Range― - ―
52-Week Range$23.08 - $32.81
Previous CloseN/A
VolumeN/A
Average Volume (3M)568.05K
Market Cap
$3.19B
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)15.18M
Price to Earnings (P/E)―
Beta0.77
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding105,326,850
10 Day Avg. Volume580,397
30 Day Avg. Volume568,050
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$47.00Price Target Upside84.53% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
---
Metsera, Inc. News
PremiumCompany Announcements
Metsera, Inc. Approves 2024 Executive Cash Bonuses
---
Bulls Say, Bears Say
Bulls Say
Market PotentialMetsera is breaking into the obesity market, which is expected to reach $170 billion by 2030, offering significant growth potential.
Pipeline And InnovationThe MOMENTUM platform is designed to significantly increase the bioavailability of oral peptides, showing further potential upside.
Strategic OpportunitiesMTSR's differentiated ultra-long-acting NuSH analog pipeline is seen as a highly promising multi-billion opportunity.
Bears Say
Competitive PositionMetsera's lead obesity assets are novel injectables with long half-lives, offering no need for dose changes during the initial phase and convenient monthly dosing during the maintenance phase.
Funding And StabilityMetsera is well-funded with enough cash to last through 2026, providing stability as they advance their clinical trials.
---
Options Prices
Currently, No data available
---
Ownership Overview
MTSR FAQ
What was Metsera, Inc.’s price range in the past 12 months?
Metsera, Inc. lowest stock price was $23.08 and its highest was $32.81 in the past 12 months.
What is Metsera, Inc.’s market cap?
Metsera, Inc.’s market cap is $3.19B.
When is Metsera, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Metsera, Inc.’s earnings last quarter?
Currently, no data Available
Is Metsera, Inc. overvalued?
According to Wall Street analysts Metsera, Inc.’s price is currently Undervalued.
Does Metsera, Inc. pay dividends?
Metsera, Inc. does not currently pay dividends.
What is Metsera, Inc.’s EPS estimate?
Metsera, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Metsera, Inc. have?
Metsera, Inc. has 105,326,850 shares outstanding.
What happened to Metsera, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Metsera, Inc.?
Currently, no hedge funds are holding shares in MTSR
---
Metsera, Inc. Stock Smart Score
Company Description
Metsera, Inc.
Metsera is a clinical-stage biotechnology company developing next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. We use our proprietary MINT peptide library of NuSH analog peptides alongside our Half-life Augmentation by Lipid Optimization, or HALO, half-life extending platform and our MOMENTUM oral NuSH analog peptide delivery platform to deliver highly differentiated product candidates that we are advancing into clinical trials for obesity or overweight. MET-097i, our most advanced product candidate, is a fully biased, monthly, subcutaneously injectable ultra-long acting GLP-1 RA that we are developing for the treatment of obesity and overweight. We have an ongoing Phase 1/2 clinical trial of MET-097i in the United States in participants who are obese or overweight but otherwise healthy.
---
MTSR Stock 12 Month Forecast
Average Price Target
$47.00
▲(84.53% Upside)
Technical Analysis
Best Analysts Covering MTSR
1 Year
1 Year Success Rate
1/1 ratings generated profit
1 Year Average Return
+1.70%
initiated a buy rating 25 days ago
Copying Seamus Fernandez's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +1.70% per trade.
---